In this Bioanalysis Zone interview, Rafiq Islam (Celerion; NE, USA) discusses the impact FDA guidance for industry on bioanalytical method validation has had on biomarker research in recent years. Rafiq also explains the advantages and disadvantages of flow cytometry as an analytical tool, before sharing his thoughts on technologies that will change biomarker research in the future.
If you enjoyed this interview, you might also like…
Bioanalysis of antibody drug conjugates using hybrid LBA/LC-MS and the BioBA Solution
Anita Tailor: the validation and standardization of biomarkers
Flow cytometry in cell-based pharmacokinetics or cellular kinetics in adoptive cell therapy